Wakefield Asset Management LLLP Sells 177 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Wakefield Asset Management LLLP cut its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.2% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 13,986 shares of the specialty pharmaceutical company’s stock after selling 177 shares during the period. Wakefield Asset Management LLLP’s holdings in ANI Pharmaceuticals were worth $891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in ANIP. Allspring Global Investments Holdings LLC raised its stake in shares of ANI Pharmaceuticals by 287.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after purchasing an additional 15,790 shares during the period. Great Lakes Advisors LLC lifted its holdings in shares of ANI Pharmaceuticals by 67.1% in the fourth quarter. Great Lakes Advisors LLC now owns 48,252 shares of the specialty pharmaceutical company’s stock worth $2,661,000 after buying an additional 19,378 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of ANI Pharmaceuticals by 106.9% in the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock valued at $1,434,000 after acquiring an additional 10,716 shares during the period. Sequoia Financial Advisors LLC purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $600,000. Finally, Lisanti Capital Growth LLC bought a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $2,218,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the completion of the transaction, the senior vice president now owns 193,226 shares in the company, valued at $12,258,257.44. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the sale, the senior vice president now owns 193,226 shares in the company, valued at $12,258,257.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Muthusamy Shanmugam sold 14,257 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total transaction of $900,472.12. Following the transaction, the chief operating officer now owns 635,363 shares of the company’s stock, valued at $40,129,527.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,007 shares of company stock worth $4,091,535. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Trading Down 0.4 %

NASDAQ ANIP opened at $60.51 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. ANI Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The stock has a market cap of $1.27 billion, a P/E ratio of 37.82 and a beta of 0.75. The stock has a 50 day simple moving average of $61.92 and a two-hundred day simple moving average of $63.95.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. During the same period in the previous year, the firm earned $1.06 EPS. The company’s quarterly revenue was up 18.5% compared to the same quarter last year. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on ANIP. Truist Financial downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $82.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.